Navigation Links
Stemedica Selected by World Stem Cell Summit to Present Scientific Discoveries
Date:8/27/2009

SAN DIEGO, Aug. 27 /PRNewswire/ -- Stemedica Cell Technologies , Inc., ("Stemedica"), a world leader in stem cell research and manufacturing (a licensed manufacturer of clinical grade biological products as licensed by the State of California Food and Drug Branch) continues to advance the stem cell industry with the presentation of two of its latest scientific discoveries at the 2009 World Stem Cell Summit. "We are honored to have the work of our scientific research team selected for presentation at this year's Summit. This work is expected to increase the efficacy and significantly reduce the time and cost in bringing important research from the bench top to clinical application," said Nikolai Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer.

The first discovery accepted by the Summit's Peer Review Committee was submitted by Chih-Min Lin, PhD, a Stemedica Senior Research Scientist. His submittal is entitled, "Chicken Embryonic Brain: A Model for Testing Neural Stem Cell Potency." This Neural Stem Cell Evaluation Model determines the potency of neural stem cells and quickly assesses their ability to migrate and engraft inside the developing brain. Stemedica's technology allows neural precursors to be distinguished at various stages of their maturation, providing timely and cost effective verification of neural stem cell potency in vivo.

"The currently used process for assessing the in vivo potency of neural stem cells in newborn mice is extremely time consuming and expensive. This traditional process also involves the use and sacrifice of animals in facilities separate from manufacturing. Stemedica's discovery and patent pending technology eliminates the need for animals and replaces this arduous process with a significantly more effective and efficacious model. This model can be deployed within laboratory environment and the evaluation results can be attained in less than two weeks instead of the two to four months using traditional animal testing models," said Alex Kharazi, MD, PhD, Stemedica's Vice President of Research and Manufacturing.

The second finding accepted for presentation at the 2009 World Stem Cell Summit was submitted by Ludmila Kharazi, MD, PhD, Stemedica's Senior Research Scientist. Her submittal is entitled, "Up-Regulation of Wound Healing Associated Proteins in Long-Term Culture of Human Keratinocyte Precursor Cells." Dr. Kharazi's work demonstrates that long term cultivation of human keratinocytes in serum free, low-Ca++ media (SFM) leads to the increased expression of genes for wound healing-associated proteins such as fibronectin, metalloproteinase (MMP9, MMP10), and tissue-type plasminogen activator (TPA). The purpose of Dr. Kharazi's work was to determine how the propagation of human skin keratinocyte precursor cells (KPC) in SFM to clinically significant numbers will affect their ability to produce fibronectin and other wound healing associated proteins.

"Current technology for the treatment of burns, chronic wounds and diabetic ulcers is extremely expensive, time consuming and lacking in efficacy. Dr. Ludmila Kharazi's finding suggests that using long term cultivated keratinocyte precursor cells may result in reducing the time of healing while lowering the overall treatment cost. As Stemedica continues to make great advancements in products that can treat burns, chronic wounds and diabetic ulcers, Dr. Ludmila Kharazi's work is pivotal in providing the Company with advancements that will make our products, and ultimately patient treatment results, the best the industry has to offer," said Dr. Tankovich. This finding compliments Stemedica's existing proprietary burn and wound care product currently in clinical trials in Switzerland.

The 2009 World Stem Cell Summit is being held in Baltimore, Maryland from September 21st - 23rd. Presented by the Genetics Policy Institute, the 2009 Summit is hosted by Johns Hopkins University and other leadership organizations from within the stem cell industry, bringing together more than 1,200 researchers, clinicians, business leaders, key policy makers, regulators, advocates, and experts in law & ethics from around the world.

Licensing of the Stemedica's Neural Stem Cell Evaluation Model Intellectual Property is available to a select number of companies. Additionally, Stemedica is prepared to accept a limited number of projects where the Company's scientific team conducts the neural stem cell potency evaluation.

About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The company is currently developing regulatory pathways for stroke and wound repair. Stemedica is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan (at)stemedica.com.


'/>"/>
SOURCE Stemedica Cell Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration
2. Stemedica Expands Globally With International Headquarters In Switzerland
3. Stemedica Announces the Appointment of Carl Bullen as Director of Manufacturing
4. Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article
5. Stemedica Advances its Certification to Become a Licensed Manufacturer of Adult Stem Cells for U.S. Based Clinical Trials
6. Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International
7. Dr Nabil Dib Takes on Special Advisor Role to the Stemedica Board of Directors
8. Greenberg Traurig Attorney Selected For Massachusetts Life Sciences Collaborative Task Force
9. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
10. Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract
11. Hypertronics Circular HyperGrip(R) Connectors Selected for Biosense Websters CARTO(R) 3 Navigation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more ... to dairy proteins, providing direct cost savings as well as more stable pricing ...
(Date:4/25/2017)... ... 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... physical therapy provider for Derby City CrossFit, effective immediately. , In addition to ... and effectively as possible, ProRehab’s sports physical therapists will work with athletes to ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental are now ... fear and require sedation to receive dental care. The doctors offer three treatment options ... hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall Centre Dental ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America ... a reputable physician in their area, announces the launch of a new and proprietary ... who are looking for reputable physicians to help them with back or neck pain ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... -- Halo Labs announces the launch of a novel ... the Horizon at PEGS 2017 in Boston ... sub visible particulate matter in biopharmaceutical samples to enable ... as candidate selection and pre-formulation. Halo Labs ... Elion Labs for system validation. "We are ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: